The New Product Category Launch is the Fourth Vascular Access Product Line to Include the Proprietary BioFlo Thromboresistant Material

Fourth quarter fiscal 2015 net sales of $90.9 million ; Full year net sales of $357 million Fourth quarter fiscal 2015 GAAP loss of $0.02 per share; Non-GAAP adjusted net income of $0.14 per share; full year non-GAAP adjusted income of $0.58 per share Fourth quarter fiscal 2015 operating cash

ALBANY, N.Y. , July 2, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 fourth

ALBANY, N.Y. , May 26, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Mark Frost , Executive Vice President and Chief Financial

ALBANY, N.Y. , May 11, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer, is

ALBANY, N.Y. , May 5, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer, is

Company Announces Worldwide Licensing Agreement With EmboMedics Inc.

Third quarter fiscal 2015 net sales of $86.6 million ; flat vs. prior year, excluding the wind down of supply agreement and $1 million on a constant currency basis GAAP loss of $0.12 per share primarily due to one-time non-cash charges Non-GAAP adjusted net income of $0.12 per share, negatively

ALBANY, N.Y. , April 7, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , March 26, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 third

ALBANY, N.Y. , Feb. 25, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , Jan. 29, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded

Second Quarter Fiscal 2015 Net Sales increased 4% to $92.1 million ; 5% sales growth excluding supply agreement GAAP EPS of $0.04 ; Non-GAAP adjusted net income of $0.17 per share, a 21% YOY increase EBITDA of $11.9 million ; Adjusted EBITDA of $15.9 million , a 18% YOY increase Company raises

ALBANY, N.Y. , Jan. 6, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer, is

ALBANY, N.Y. , Dec. 17, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2015 second

ALBANY, N.Y. , Dec. 9, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it signed an agreement with HealthTrust covering PICC

ALBANY, N.Y. , Nov. 25, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo , President and Chief Executive Officer,

ALBANY, N.Y. , Nov. 11, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences

ALBANY, N.Y. , Oct. 28, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the Germany Ministry of Health has issued an OPS (a procedure

ALBANY, N.Y. , Oct. 13, 2014 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today it will be added to the S&P SmallCap 600 Index and the GICS Life